#AANAM – Vumerity Showing Tolerability, Efficacy in Ongoing EVOLVE-MS-1 Trial

#AANAM – Vumerity Showing Tolerability, Efficacy in Ongoing EVOLVE-MS-1 Trial

293065

#AANAM – Vumerity Showing Tolerability, Efficacy in Ongoing EVOLVE-MS-1 Trial

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Vumerity (diroximel fumarate) continues to be safe and well-tolerated, in addition to reducing measures of disease activity in people with relapsing-remitting multiple sclerosis (RRMS), according to updated data from the ongoing EVOLVE-MS-1 Phase 3 clinical trial. These interim results were delivered by Sibyl Wray, MD, in the poster “Interim…

You must be logged in to read/download the full post.